Formatech, Inc.'s "Fillanthropy Program" Donates Services to Formulate and Fill ViroMed's VM206 Vaccine Targeting Breast Cancer  
1/5/2010 9:40:51 AM

ANDOVER, Mass.--(BUSINESS WIRE)--Today, Formatech has selected the next candidate for its Fillanthropy Program: ViroMed’s VM206 therapeutic cancer vaccine. Under the Fillanthropy Program, Formatech will donate the services required to aseptically fill and finish one lot of the vaccine to support ViroMed’s upcoming clinical trials. Formatech plans to complete the production run in March 2010.